SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+1.14%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$205K
AUM Growth
+$205K
(-100%)
Cap. Flow
-$38.7M
Cap. Flow
% of AUM
-18,901.35%
Top 10 Holdings %
Top 10 Hldgs %
33.05%
Holding
123
New
32
Increased
38
Reduced
21
Closed
29
Top Buys
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$12.8K |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.29K |
| 3 |
MacroGenics
MGNX
|
$4.75K |
| 4 |
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
|
$3.76K |
| 5 |
Veracyte
VCYT
|
$3.63K |
Top Sells
| 1 |
Vericel Corp
VCEL
|
$6.78M |
| 2 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
$4.01M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$2.87M |
| 4 |
Larimar Therapeutics
LRMR
|
$2.8M |
| 5 |
ESSA Pharma
EPIX
|
$2.13M |
Sector Composition
| 1 | Healthcare | 86.9% |
| 2 | Financials | 6.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
United Therapeutics
UTHR
$13.8B
| $2.74K | 1.22% | 15,289 +9,925 | +185% | +$1.78K |
|
|
SRRA
27
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.71K | 1.21% | 139,305 +4,624 | +3% | +$90 |
|
|
DNAB
28
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
| $2.53K | 1.13% | +250,000 | New | +$2.53K |
|
29
ProKidney
PROK
$319M
| $2.53K | 1.13% | +250,000 | New | +$2.53K |
|
|
AKLI
30
DELISTED
Akili, Inc. Common Stock
AKLI
| $2.53K | 1.13% | +250,000 | New | +$2.53K |
|
|
DNAD
31
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
| $2.53K | 1.13% | +250,000 | New | +$2.53K |
|
32
MoonLake Immunotherapeutics
MLTX
$3.54B
| $2.42K | 1.08% | 234,020 +5,535 | +2% | +$57 |
|
33
NextCure
NXTC
$13.5M
| $2.29K | 1.02% | +285,498 | New | +$2.29K |
|
34
Aldeyra Therapeutics
ALDX
$351M
| $2.18K | 0.97% | 192,345 -129,534 | -40% | -$1.47K |
|
35
EyePoint Pharmaceuticals
EYPT
$797M
| $2.18K | 0.97% | 242,309 -57,691 | -19% | -$519 |
|
|
OTIC
36
DELISTED
Otonomy, Inc.
OTIC
| $2.13K | 0.95% | 953,434 +702,439 | +280% | +$1.57K |
|
37
Curis
CRIS
$20.9M
| $2.09K | 0.93% | 259,539 -369,254 | -59% | -$2.98K |
|
38
Benitec Biopharma
BNTC
$348M
| $1.99K | 0.89% | +467,256 | New | +$1.99K |
|
39
Cullinan Oncology
CGEM
$445M
| $1.95K | 0.87% | +75,732 | New | +$1.95K |
|
40
VistaGen Therapeutics
VTGN
$102M
| $1.94K | 0.86% | +615,547 | New | +$1.94K |
|
41
iTeos Therapeutics
ITOS
| $1.94K | 0.86% | +75,511 | New | +$1.94K |
|
42
Zentalis Pharmaceuticals
ZNTL
$122M
| $1.85K | 0.82% | +34,725 | New | +$1.85K |
|
43
Compugen
CGEN
$132M
| $1.73K | 0.77% | 209,113 +134,113 | +179% | +$1.11K |
|
44
Kura Oncology
KURA
$686M
| $1.72K | 0.77% | 82,573 +2,573 | +3% | +$54 |
|
|
AFMD
45
DELISTED
Affimed
AFMD
| $1.72K | 0.77% | 202,190 -300,140 | -60% | -$2.55K |
|
|
JNCE
46
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.7K | 0.76% | 250,644 -99,356 | -28% | -$675 |
|
47
Mersana Therapeutics
MRSN
$36.5M
| $1.7K | 0.76% | 125,123 +100,123 | +400% | +$1.36K |
|
|
CERE
48
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.66K | 0.74% | +15,000 | New | +$1.66K |
|
49
Cogent Biosciences
COGT
$1.69B
| $1.61K | 0.72% | 198,245 +78,245 | +65% | +$635 |
|
50
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $1.53K | 0.68% | 257,958 +7,958 | +3% | +$47 |
|